NewcelX Ltd. (NCEL) — RQD Stock Rating Cockpit

NCEL scores 30 out of 100, grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine 5/20 (ROIC -35%; FCF yield -17.84%); Whale 13F Flow 5/20 (institutional accumulation and options positioning); Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 7/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5).

Read together, the pillars point to weak cash generation as the dominant issue. The balance sheet pillar sits at the middle of the range, with a Z-Score of 2.5 and a Piotroski F-Score of 1/9, which signals weak financial health on the nine-point scale. For a prospective investor, the upside case rests almost entirely on a turnaround in cash generation that the current data does not show, while the valuation case is complicated by the absence of earnings-based multiples in the source data. The rating's stated verdict is avoidance, and the supporting facts in this dossier are consistent with that framing.

NewcelX Ltd. (NCEL) is a NASDAQ-listed operating company in the Biotechnology: Pharmaceutical Preparations industry (Health Care sector) with an equity market capitalization of $14.7M. The business operates with a gross margin of 0%, an operating margin of 0%, and a return on invested capital (ROIC) of -35% (free cash flow yield of -17.84%). Within the Biotechnology: Pharmaceutical Preparations peer group, investor evaluation centers on operating leverage, unit margin durability, and capital allocation efficiency across market cycles.

All three periods report operating and net losses, with revenue at —, and gross, operating, and net margins are each 0% per the market data. ROIC is -35% per the market data. The Altman Z-Score of 2.5 and Piotroski F-Score of 1/9 are cited in the Roarable RQD rating, and Debt/Equity of 0.5 is also taken from that section.

• 🐂 Primary Bull Case: Price sits near the low end of its 52-week range at $2.69 against a $1.83 low, with beta of 1.0 and a $2.2M cash balance in FY 2025. With Fundamental Cash Engine at 5/20 (ROIC -35.0%, FCF yield -17.84%) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $1.83 – $6.48 52-week range.
• 🐻 Primary Bear Case: Reported revenue is $0.0M across three fiscal years while net losses of -$8.3M in FY 2025 and a ROIC of -35% show persistent cash consumption. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

The source data therefore does not establish upstream or downstream dependencies, sector correlations beyond the stated beta of 1.0, or second-order bottlenecks. A prospective investor should note that the absence of mapped links is itself a data limitation rather than evidence of independence.

• Key Question #1: What are the debt terms behind the reported Debt/Equity of 0.5 when period-level debt is listed as N/A?
• Key Question #2: What EPS, P/E, and EV/EBITDA figures would apply once earnings are reported, given that all earnings-based multiples are currently absent?
• Key Question #3: How sensitive is NCEL's — gross margin and equity valuation to Health Care demand cycles and macro interest-rate shifts (Beta 1.00)?